AstraZeneca share price: Q1 2022 results preview
Astrazeneca Q1 results are expected to see revenue and earnings growth despite slowing Covid-19 vaccine sales.
When are the AstraZeneca results?
The AstraZeneca the biopharmaceutical company, earnings release date is scheduled for 29 April 2022. The scheduled results will cover the groups first fiscal quarter of the year quarter one (Q1) 2022 ending March 2022.
What to expect from AstraZeneca results?
Unlike competitors Pfizer and Moderna, Astrazeneca has previously (in 2021) only offered its Covid-19 vaccine for non-profit. The year 2022 will however see the group selling its vaccine at varying (to maintain affordability), but marginal profit levels. This is expected to help add to bottom lines, although sales of the preventative Covid-19 treatment is expected to wane as the ‘pandemic’ moves to ‘endemic’ stage. Take-up of the vaccine is expected to remain strong in middle income jurisdictions such as Latin America, Southeast Asia, and the Middle East.
Revenue and earnings for the group are guided to be supported by new drugs for cancer, kidney and rare diseases. Last years acquisition of Alexon will see this quarter reflecting earnings thereto not reflected in the prio year’s comparative.
Consensus estimates from Refinitiv data arrives at the following expectations for quarter two (Q2) 2021:
- Revenue $10.792 :+47.3% year on year (YoY)
- Earnings Before Interest Tax Depreciation and Amortisation (EBITDA) $3.696 billion +11.2% (YoY)
- Earnings per share (EPS) $1.71 : +4.78% (YoY)
How to trade AstraZeneca results
A Refinitiv poll of 31 analysts maintain a long-term average rating of ‘buy’ for AstraZeneca (as of 22 April 2022), with eight of these analysts recommending a strong buy, 20 recommending a buy 2 hold and 1 sell recommendation on the stock.
AstraZeneca share price: Technical Analysis View
The share price of AstraZeneca remains in a long-term uptrend. In the short term, we are seeing a correction of the long-term uptrend from what was overbought territory.
In lieu of the primary trend still being up, our preference remains in keeping a long bias to trades on the stock. The pullback from highs sees the 9460 as a possible downside target from the move. We are looking for a bullish price reversal before the 9460 level for long entry, with 10910 the upside target.
Summary
- AstraZeneca results are scheduled for release on 29 April 2022
- Q2 2022 revenue of $10.792 : +47.3% (YoY) expected
- Q1 2022 EBITDA of $3.696 billion : +11.2% (YoY) expected
- EPS of $1.71 : +4.98 (YoY) is expected
- The average broker rating for AstraZeneca is ‘buy’
- The AstraZeneca share price is currently in a short-term correction of a longer-term uptrend
This information has been prepared by IG, a trading name of IG Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients.
CFDs are a leveraged products. CFD trading may not be suitable for everyone and can result in losses that exceed your initial deposit, so please ensure that you fully understand the risks involved.
Act on stock opportunities today
Go long or short on thousands of international stocks with CFDs.
- Get full exposure for a comparatively small deposit
- Trade on spreads from just 0.1%
- Get greater order book visibility with direct market access
See opportunity on a stock?
Try a risk-free trade in your demo account, and see whether you’re on to something.
- Log in to your demo
- Try a risk-free trade
- See whether your hunch pays off
See opportunity on a stock?
Don’t miss your chance – upgrade to a live account to take advantage.
- Trade a huge range of popular stocks
- Analyse and deal seamlessly on fast, intuitive charts
- See and react to breaking news in-platform
See opportunity on a stock?
Don’t miss your chance. Log in to take advantage while conditions prevail.
Live prices on most popular markets
- Forex
- Shares
- Indices
Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.
